A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain
Phase of Trial: Phase II
Latest Information Update: 15 Aug 2017
At a glance
- Drugs KLH 2109 (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Acronyms EDELWEISS
- Sponsors ObsEva
- 15 Aug 2017 According to an ObsEva media release, enrollment in the European sites is complete while US recruitment remains ongoing. Completion of enrollment is expected in late 2017 or early 2018, with data expected from the first 12-week evaluation period around mid-2018.
- 18 May 2017 According to an ObsEva media release, completion of enrollment of this trial is expected by the end of 2017, with data release planned 1H 2018.
- 02 Mar 2017 Planned End Date changed from 1 Apr 2018 to 1 May 2019.